Publications by authors named "Meredith G Faggen"
Background: The expansion of hematopoietic stem cells carrying recurrent somatic mutations, termed clonal hematopoiesis (CH), is common in elderly individuals and is associated with increased risk of myeloid malignancy and all-cause mortality. Though chemotherapy is a known risk factor for developing CH, how myelosuppressive therapies affect the short-term dynamics of CH remains incompletely understood. Most studies have been limited by retrospective design, heterogeneous patient populations, varied techniques to identifying CH, and analysis of single timepoints.
View Article and Find Full Text PDFIntroduction: Older adults with breast cancer receiving neo/adjuvant chemotherapy are at high risk for poor outcomes and are underrepresented in clinical trials. The ADVANCE (ADjuVANt Chemotherapy in the Elderly) trial evaluated the feasibility of two neo/adjuvant chemotherapy regimens in parallel-enrolling cohorts of older patients with human epidermal growth factor receptor 2-negative breast cancer: cohort 1-triple-negative; cohort 2-hormone receptor-positive.
Materials And Methods: Adults age ≥ 70 years with stage I-III breast cancer warranting neo/adjuvant chemotherapy were enrolled.
Article Synopsis
- The study investigates chemotherapy-related amenorrhea (CRA) as an indicator of ovarian toxicity and its implications for women's fertility and menopause risks, comparing rates between two treatments: paclitaxel-trastuzumab (TH) and ado-trastuzumab emtansine (T-DM1).
- Patients with early-stage HER2-positive breast cancer from the ATEMPT trial were monitored for menstrual changes over 18 months after receiving either TH or T-DM1, with findings showing a 50% CRA rate in TH recipients compared to 24% in T-DM1 recipients (p=0.045).
- The conclusion emphasizes that T-DM1 is associated with a lower